Halozyme Therapeutics Inc (HALO)

NASDAQ
57.05
+0.58(+1.03%)
Pre Market
57.05
0.00(0.00%)
- Real-time Data
  • Volume:
    1,359,346
  • Day's Range:
    55.64 - 57.07
  • 52 wk Range:
    31.36 - 57.67

HALO Overview

Prev. Close
56.47
Day's Range
55.64-57.07
Revenue
580.62M
Open
56.13
52 wk Range
31.36-57.67
EPS
1.53
Volume
1,359,346
Market Cap
7.71B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,168,340
P/E Ratio
38.24
Beta
1.22
1-Year Change
71.42%
Shares Outstanding
135,213,058
Next Earnings Date
Feb 21, 2023
What is your sentiment on Halozyme?
or
Market is currently closed. Voting is open during market hours.

Halozyme Therapeutics Inc News

Halozyme Therapeutics Inc Analysis

Halozyme Therapeutics Inc Company Profile

Halozyme Therapeutics Inc Company Profile

Employees
145

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Read More

Analyst Price Target

Average53.22 (-6.71% Downside)
High65
Low23
Price57.05
No. of Analysts10
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • Korea's Biotech Alteogen Technology surpasses HALO
    0
    • alteogen
      0
      • very good fundamentals. technical also good. If it keeps rising until the EOY rally, this could be a big deal.
        1